Faculty profile

Helen MacKay

Back to faculty

ProfessorDepartment of MedicineUniversity of Toronto

Helen MacKay

Professor

Department of Medicine

Temerty Faculty of Medicine

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Professors usually supervise graduate students in their department's programs.
9 publications in the last five years, latest in 2026.
Senior (last) author on 2 recent papers, a sign of leading a research group.

These signals come from public records, including federal and provincial funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

438

Citations

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

University Profile

Search on Google Scholar

Search on ResearchGate

iDORCID OpenAlex

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their University of Toronto profile.

Latest papers

Evaluating the clinical utility and impact on healthcare utilization of serial troponin T monitoring in gynecologic cancer patients receiving immune checkpoint inhibitors - A single centre experience.
Gynecologic oncology · 2026 · senior author
Consensus Statement from the Society of Gynecologic Oncology of Canada on Folate Receptor α Testing in Ovarian Cancer.
Current oncology (Toronto, Ont.) · 2026
HER2 Expression in Squamous Cell Carcinoma of the Vulva: A Systematic Review and Meta-Analysis.
Cancers · 2026

All 25 publications

Latest funding

Refining Adjuvant treatment IN endometrial cancer Based On molecular features (RAINBO) No Specific Molecular Profile (NSMP)-ORANGE trial
CIHR · 2026 · Co-investigator
$1,575,898
Targeting cancer cell plasticity to improve outcomes in high-grade serous ovarian cancer
CIHR · 2025 · Co-investigator
$1,025,100
RAINBO: Refining Adjuvant treatment IN endometrial cancer Based On molecular features, TransPORTEC platform trials - The MMRD-GREEN trial
CIHR · 2022 · Co-investigator
$761,175

All 6 grants and awards

25 publications.

Evaluating the clinical utility and impact on healthcare utilization of serial troponin T monitoring in gynecologic cancer patients receiving immune checkpoint inhibitors - A single centre experience.

Fernandes I, Sachdeva A, Tavangar F, Lafreniere M, Yip P, Petrella T, Thavendiranathan P, MacKay H

Gynecologic oncology20262 citationsSenior authorOpen Access

DOI: 10.1016/j.ygyno.2025.12.003 PMID: 41380303

Consensus Statement from the Society of Gynecologic Oncology of Canada on Folate Receptor α Testing in Ovarian Cancer.

Ma K, Tessier-Cloutier B, Altman AD, Carey MS, Ethier JL, Lau S, Lee CH, Hopkins L, Kieser K, Kumar A, Leung SOA, Nguyen JMV, MacKay H, McGee J, Salman L, Salvador S, Sluce C, Tatar L, Tone AA, Tinker A, Tremblay E, Veneziani AC, Vicus D, Welch S, Windsor Harker S, Brodeur MN

Current oncology (Toronto, Ont.)2026Open Access

DOI: 10.3390/curroncol33060330 PMID: 42346230

HER2 Expression in Squamous Cell Carcinoma of the Vulva: A Systematic Review and Meta-Analysis.

Farias Müller NL, Sibani MA, Ayoub Y, Ayoub M, Pullattayil AK, Tavangar F, Plotkin A, George S, Jerzak KJ, Mackay H, Chehade R

Cancers2026

DOI: 10.3390/cancers18132162 PMID: 42449705

Brain metastases among patients with gynecologic cancers: a single-centre retrospective study of patients treated with brain radiotherapy.

Chehade R, Al-Humiqani A, Hanna L, Sahgal A, Moravan V, Das S, Soliman H, Mackay H, Jerzak KJ

Journal of neuro-oncology2026

DOI: 10.1007/s11060-026-05513-7 PMID: 41838212

Lenvatinib plus pembrolizumab in participants with advanced or recurrent endometrial cancer: Study 309/KEYNOTE-775 and ENGOT-en9/LEAP-001 post-(neo)adjuvant therapy outcomes.

Marth C, Lorusso D, Bidziński M, Scollo P, Vardar MA, Oaknin A, Kaen DL, Nogueira-Rodrigues A, Miller DS, Hasegawa K, MacKay H, Moore RG, Santin AD, Yunokawa M, Romero I, Pignata S, Baron-Hay S, Kim YM, Amit A, Ghamande S, Danska-Bidzinska A, Tarnawski R, Wang PH, Yu Z, Slomovitz BM, Okpara CE, McKenzie J, Meng R, Orlowski R, Makker V

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society2026

DOI: 10.1016/j.ijgc.2026.104693 PMID: 42167105

Putting Patients First: Pragmatic Trials in Gynecologic Oncology.

Hopkins L, Clemons M, Bemister K, Booth C, Kadar S, Karanicolas P, Mulligan J, Savard MF, Tannock I, Tone A, MacKay H

Current oncology (Toronto, Ont.)20251 citationsSenior authorOpen Access

DOI: 10.3390/curroncol32030139 PMID: 40136343

Randomized study evaluating optimal dose, efficacy, and safety of E7386 plus lenvatinib versus treatment of physician's choice in advanced/recurrent endometrial carcinoma previously treated with platinum-based chemotherapy and immune checkpoint inhibitors.

Eskander RN, Lee JY, Mirza MR, Lorusso D, MacKay H, Ray-Coquard I, Oaknin A, Gonzalez-Martin A, Hasegawa K, Corr BR, Wu X, Leary A, Hu T, Dutta L, Okpara CE, McKenzie J, Makker V

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society2025

DOI: 10.1016/j.ijgc.2025.101812 PMID: 40318924

Clinical Validation of Human Papilloma Virus Circulating Tumor DNA for Early Detection of Residual Disease After Chemoradiation in Cervical Cancer.

Han K, Zou J, Zhao Z, Baskurt Z, Zheng Y, Barnes E, Croke J, Ferguson SE, Fyles A, Gien L, Gladwish A, Lecavalier-Barsoum M, Lheureux S, Lukovic J, Mackay H, Marchand EL, Metser U, Milosevic M, Taggar AS, Bratman SV, Leung E

Journal of clinical oncology : official journal of the American Society of Clinical Oncology202474 citationsOpen Access

DOI: 10.1200/jco.23.00954 PMID: 37972346

Quality-of-Life Outcomes and Toxic Effects Among Patients With Cancers of the Uterus Treated With Stereotactic Pelvic Adjuvant Radiation Therapy

Leung E, Gladwish AP, Davidson M, Taggar A, Velker V, Barnes E, Mendez L, Donovan E, Gien LT, Covens A

JAMA Oncology202231 citationsOpen Access

DOI: 10.1001/jamaoncol.2022.0362

Factors impacting length of stay and survival in patients with advanced gynecologic malignancies and malignant bowel obstruction

Melissa Tigert, Christine L. Lau, Helen J MacKay, Stéphanie Lheureux, Lilian Tran Gien

International Journal of Gynecological Cancer202110 citationsOpen Access

DOI: 10.1136/ijgc-2020-002133 PMID: 33509803

Profile data last refreshed on September 29, 2026 from the university directory, publication records and public research funding records.

Something wrong or missing on this profile? Suggest a correction

Helen MacKay

Research

Latest papers

Latest funding

Evaluating the clinical utility and impact on healthcare utilization of serial troponin T monitoring in gynecologic cancer patients receiving immune checkpoint inhibitors - A single centre experience.

Consensus Statement from the Society of Gynecologic Oncology of Canada on Folate Receptor &#x3b1; Testing in Ovarian Cancer.

HER2 Expression in Squamous Cell Carcinoma of the Vulva: A Systematic Review and Meta-Analysis.

Brain metastases among patients with gynecologic cancers: a single-centre retrospective study of patients treated with brain radiotherapy.

Lenvatinib plus pembrolizumab in participants with advanced or recurrent endometrial cancer: Study 309/KEYNOTE-775 and ENGOT-en9/LEAP-001 post-(neo)adjuvant therapy outcomes.

Putting Patients First: Pragmatic Trials in Gynecologic Oncology.

Randomized study evaluating optimal dose, efficacy, and safety of E7386 plus lenvatinib versus treatment of physician's choice in advanced/recurrent endometrial carcinoma previously treated with platinum-based chemotherapy and immune checkpoint inhibitors.

Clinical Validation of Human Papilloma Virus Circulating Tumor DNA for Early Detection of Residual Disease After Chemoradiation in Cervical Cancer.

Quality-of-Life Outcomes and Toxic Effects Among Patients With Cancers of the Uterus Treated With Stereotactic Pelvic Adjuvant Radiation Therapy

Factors impacting length of stay and survival in patients with advanced gynecologic malignancies and malignant bowel obstruction

Refining Adjuvant treatment IN endometrial cancer Based On molecular features (RAINBO) No Specific Molecular Profile (NSMP)-ORANGE trial

Targeting cancer cell plasticity to improve outcomes in high-grade serous ovarian cancer

RAINBO: Refining Adjuvant treatment IN endometrial cancer Based On molecular features, TransPORTEC platform trials - The MMRD-GREEN trial

Tailored adjuvant therapy in POLE-mutated and p53-wildtype early stage endometrial cancer (TAPER)

X-chromosome wide genetic association on cancer prognostic and pharmacogenetic analysis of clinical trials: methodological development and analysis

The Pharmacogenetics of Bevacizumab: A Companion Correlative Study of the Ovarian Cancer Clinical Trial, ICON7

Frequent collaborators

Danielle Vicus

Amit Oza

Sarah Ferguson

Michael Milosevic

Stephanie Lheureux

Geoffrey Liu

Stéphane Laframboise

Laura Hopkins

Monika Krzyzanowska

Rania Chehade

Eric Leung

Kathy Han

Blaise Clarke

David Hedley

Elizabeth Barnes

Lillian Siu

Anthony Fyles

Ian Tannock

Rachel Kupets

Joan Murphy

Ur Metser

Ming Tsao

Masoom Haider

John Kim

Anna Tinker

Arjun Sahgal

Jelena Lukovic

Jennifer Croke

Shuk Leung

Consensus Statement from the Society of Gynecologic Oncology of Canada on Folate Receptor α Testing in Ovarian Cancer.